ITI-333 is a drug which has a mixed mechanism of action, acting as an antagonist at the 5-HT2A, D1 and α1A receptors, and also as a partial agonist at the μ-opioid receptor. In animal studies it blocked the head-twitch response produced by DOI and also reduced responses to morphine, while also reducing the symptoms produced by naloxone-precipitated withdrawal in opioid habituated mice. It has been developed for potential uses in treatment of opioid withdrawal and opioid use disorder.[1][2]
![]() | |
Identifiers | |
---|---|
| |
PubChem CID | |
Chemical and physical data | |
Formula | C22H24FN3O |
Molar mass | 365.452 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Li P, Zhang Q, Zheng H, Qiao Y, Snyder GL, Martin T, et al. (June 2024). "Discovery of ITI-333, a Novel Orally Bioavailable Molecule Targeting Multiple Receptors for the Treatment of Pain and Other Disorders". Journal of Medicinal Chemistry. 67 (11): 9355–9373. doi:10.1021/acs.jmedchem.4c00480. PMC 11181336. PMID 38805667.
- ^ Snyder GL, Li P, Martin T, Zhang L, Yao W, Zheng H, et al. (July 2024). "Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders". Psychopharmacology. 241 (7): 1477–1490. doi:10.1007/s00213-024-06578-w. PMC 11199232. PMID 38710856.